- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01008319
Traditional Clomiphene Citrate Administration vs. Stair-step Approach (Clomid)
Traditional Clomiphene Citrate Administration Versus a Stair-Step Approach: A Randomized Controlled Trial
The purpose of this study is to compare the length of time to achieve ovulation and pregnancy with a traditional protocol administration of clomiphene citrate versus a stair step administration.
Our hypothesis is by using a stair-step approach in which a period is not induced between administrations of escalating doses of clomiphene citrate, the time to ovulation and pregnancy may be reduced.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The traditional administration of clomiphene citrate for ovulation induction involves taking clomiphene citrate for 5 days. If ovulation does not occur within 14 days, a progestin pill (such as Provera) is prescribed for 10 days to induce a period (which normally occurs within 1 week of stopping the pill). Then a higher dose of clomiphene citrate will be prescribed.
The stair-step administration of clomiphene citrate for ovulation induction also involves taking clomiphene citrate for 5 days. In contrast, if ovulation does not occur within 7-9 days, a progestin pill (such as Provera) would NOT be taken to induce a period. The dose of clomiphene will then be increased. Therefore, this would do away with the 10 days of taking the progestin pill, and also do away with waiting for a period (usually 3 to 7 days) for a total of up to a 20 day difference between clomiphene citrate dosing cycles.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73013
- University of Oklahoma Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ovulatory dysfunction as evidenced by mid-luteal progesterone less then 3ng/dL, non-biphasic basal body temperature charting, or menstrual history of cycles > 35 days.
- Female patients 18 to 45 years old
- Six months or greater of unprotected intercourse without pregnancy.
- Normal TSH and prolactin serum levels
Semen analysis of male partner with > 15 million motile sperm on semen analysis.
- NOTE: Must be willing to travel to the Oklahoma City area for treatment.
Exclusion Criteria:
- Failure to spontaneously menstruate or to menstruate following progestin administration
- Allergy or intolerance to the side effects of clomiphene citrate, hCG (human chorionic gonadotropins), or medroxyprogesterone acetate (Provera).
- Known anatomical defect affecting the uterine cavity including submucosal fibroids or endometrial polyps.
- Know tubal hydrosalpinx or risk factors for tubal obstruction
- Known liver dysfunction
- Known or suspected androgen secreting tumor, cushings disease, or adrenal hyperplasia (congenital or adult onset)
- Ovarian cyst > 20mm or endometrial lining >6 mm on trans-vaginal baseline ultrasound.
- Stage III or IV endometriosis
- Decreased ovarian reserve as evidenced by antral follicle count less than 6 by Transvaginal ultrasound or a cycle-day-3 serum FSH of > 10 uIU/ml.
- Positive HIV in either the female patient or her partner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Traditional Administration
The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5).
If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
|
Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle.
If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose.
Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days.
Increased dose of clomiphene citrate for 5 days starting on cycle day 5.
This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Other Names:
Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle.
If NO dominant follicle present, a blood draw (to test progesterone level) will be done.
Increased dose of clomiphene citrate for 5 days starting that day.
A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle.
This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Other Names:
|
Experimental: Stair-Step Administration
The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period.
This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid.
If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg.
Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol.
This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
|
Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle.
If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose.
Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days.
Increased dose of clomiphene citrate for 5 days starting on cycle day 5.
This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Other Names:
Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle.
If NO dominant follicle present, a blood draw (to test progesterone level) will be done.
Increased dose of clomiphene citrate for 5 days starting that day.
A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle.
This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Ovulation With Each Protocol
Time Frame: 5 years
|
We hypothesized that time to ovulation would be shorter with stair-step protocol vs. traditional.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Ovulation
Time Frame: 5 years
|
Rate of ovulation with each dose of clomid within each protocol
|
5 years
|
Delivery Outcomes
Time Frame: 5 years
|
Proportion of participants that delivered a baby based on which protocol they were randomized to.
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: LaTasha Craig, MD, University of Oklahoma
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Anovulation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Anticoagulants
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Chelating Agents
- Sequestering Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Calcium Chelating Agents
- Citric Acid
- Sodium Citrate
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- 2078
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anovulation
-
University of South FloridaWithdrawn
-
Benha UniversityCompletedInfertility, Female, Associated With AnovulationEgypt
-
Ahmed Fathy Ali Mohamed GhanemCompletedFemale Infertility Associated With Anovulation
-
GeneScience Pharmaceuticals Co., Ltd.Peking University First Hospital; Peking University People's Hospital; Qilu Hospital... and other collaboratorsCompleted
-
Rigshospitalet, DenmarkHolbaek SygehusCompletedInfertility | AnovulationDenmark
-
Assiut UniversityCompleted
-
EMD SeronoCompleted
-
Ferring PharmaceuticalsCompleted
-
Organon and CoCompleted
-
Mount Sinai Hospital, CanadaCompleted
Clinical Trials on clomiphene citrate
-
Dinesh Khanna, MD, MSBayerCompletedScleroderma | Digital UlcersUnited States
-
Xiyuan Hospital of China Academy of Chinese Medical...Dongzhimen Hospital, Beijing; Beijing Hospital of Traditional Chinese Medicine and other collaboratorsUnknownPolycystic Ovarian Syndrome | Hyperprolactinemia | Anovulatory Infertility | Abnormal Uterine Bleeding-Ovulatory Disorders | Luteinized Unruptured Follicle Syndrome | Corpus Luteum Insufficiency | Ovarian Insufficiency
-
Weill Medical College of Cornell UniversityRecruitingTestosterone DeficiencyUnited States
-
Mansoura UniversityCompletedPolycystic Ovary SyndromeEgypt
-
University Magna GraeciaUnknownAnovulatory Infertility Related to Polycystic Ovary SyndromeItaly
-
The Cleveland ClinicWithdrawnInfertility | EndometriosisUnited States
-
University of AthensLito Maternity HospitalUnknown
-
The Egyptian IVF-ET CenterUnknown
-
Royan InstituteCompletedInfertilityIran, Islamic Republic of